Skip to main content
. Author manuscript; available in PMC: 2016 Jun 24.
Published in final edited form as: Breast Cancer Res Treat. 2012 Nov 6;137(1):45–56. doi: 10.1007/s10549-012-2279-y

Figure 4.

Figure 4

Recurrent disease development in patients with ERBB2-positive DTCs. Patients with Her2 positive tumors received chemotherapy with trastuzumab. Patients with Her2-negative tumors received cytotoxic chemotherapy alone. All patients had ERBB2-positive DTCs. All recurrences detected within 24 months (mean=19) of diagnosis.